Loading quotes...

Forecast

The analysts' average price target is €173.09 (+38.47%). The median is €173.09 (+38.47%).

Buy	2
Hold	1
Sell	0

News Go to news feed

Novanta reaches new 52-week high after strong Q2 results

Novanta stock rose to $172.31, marking a new 52-week high, driven by a 34.62% gain over the past year and a 28.68% year-to-date increase. The company beat expectations in Q2 with adjusted earnings of $0.89 per share and revenue of $265.8 million, reported 9% organic revenue growth and a 16% rise in adjusted EBITDA. Analysts warn of possible overvaluation; the P/E ratio is 109.36, market capitalization is $6.31 billion, and the company has raised its outlook. » More on de.investing.com
Novanta reports 37% rise in bookings and broadening organic demand, Conestoga says

Conestoga Capital highlighted Novanta as a top contributor, citing improving demand across robotics, medical technologies, semiconductor equipment and AI-related applications. Management raised its revenue outlook after bookings increased 37% year-over-year, reinforcing confidence in widening organic growth across the portfolio. Conestoga expects Novanta's momentum to continue as market leadership broadens. » More on finance.yahoo.com
Novanta acquires Riverpoint Medical for up to $1.45 billion

Novanta has agreed to acquire Riverpoint Medical for $1.2 billion in cash plus a $250 million milestone payment, with closing expected in the third quarter of 2026 subject to approvals. The acquisition is intended to double recurring revenue from medical consumables to around $300 million and raise the share of the medical end market to 60%. The purchase price equals roughly 19 times estimated adjusted EBITDA for 2026 (17 times including synergies); Novanta expects adjusted EBITDA of about $80 million for 2027 including synergies. Financing will come from cash, the existing credit facility and a recently completed equity raise; net leverage is expected to be about 2.7x after closing, with a target of under 2.3x by the end of 2027. » More on de.investing.com

Financials

In the last quarter, Novanta had revenue of €232.29m and net profit of €10.96m

(EUR)	July 2026	YoY
Revenue	232.29m	12.93%
Gross profit	105.67m	23.99%
Net profit	10.96m	185.61%
EBITDA	27.66m	19.24%

Fundamentals

Metric	Value
Market capitalization	€4.74bn
Number of shares	37.82m
52-week high/low	€157.37 - €87.68
Dividends	No
Beta	1.72
P/E ratio	88.28
PEG ratio	-13.64
P/B ratio	3.56
P/S ratio	5.16

Company profile

Novanta Inc., together with its subsidiaries, designs, manufactures, markets, and sells photonics, vision, and precision motion components and sub-systems to original equipment manufacturers in the medical and industrial markets worldwide. The company's Photonics segment offers photonics-based solutions, including laser scanning and beam delivery, CO2 laser, solid state laser, ultrafast laser, and optical light engine products serving photonics-based applications for industrial processing, metrology, medical and life science imaging, DNA sequencing, and medical laser procedures. It's Vision segment provides a range of medical grade technologies, including medical insufflators, pumps, and related disposables; visualization solutions; wireless technologies, video recorders, and video integration technologies for operating room integrations; optical data collection and machine vision technologies; radio frequency identification technologies; thermal chart recorders; spectrometry technologies; and embedded touch screen solutions. In addition, its Precision Motion segment offers optical and inductive encoders, precision motors, servo drives and motion control solutions, integrated stepper motors, intelligent robotic end-of-arm technology solutions, air bearings, and air bearing spindles. The company sells its products through its direct sales force, resellers, distributors, and system integrators under the Cambridge Technology, Synrad, Laser Quantum, ARGES, WOM, NDS, NDSsi, Med X Change, Reach Technology, JADAK, ThingMagic, Photo Research, Celera Motion, MicroE, Zettlex, Applimotion, Ingenia, and Westwind brands. The company was formerly known as GSI Group, Inc. and changed its name to Novanta Inc. in May 2016. Novanta Inc. was founded in 1968 and is headquartered in Bedford, Massachusetts.